Radiobiological rationale and clinical implications of hypofractionated radiation therapy

Cancer/Radiotherapie

Volumn 15, Issue 3, 2011, Pages 221-229

  Ko, E C ^a   Forsythe, K ^a   Buckstein, M ^a   Kao, J ^a   Rosenstein, B S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Breast cancer; Hypofractionation; Prostate cancer; Radiation therapy; Stereotactic body radiotherapy; Stereotactic radiosurgery

Indexed keywords

BIOLOGICAL THERAPY; BRACHYTHERAPY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTRAOPERATIVE RADIOTHERAPY; LUNG CANCER; OVERALL SURVIVAL; PARTIAL BREAST IRRADIATION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION DOSE HYPOFRACTIONATION; RADIATION INJURY; RADIOBIOLOGY; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAFETY; SHORT SURVEY; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC RADIOSURGERY;

ADENOCARCINOMA; BIOLOGICAL THERAPY; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; FORECASTING; HUMANS; INTRAOPERATIVE CARE; LUNG NEOPLASMS; MALE; MULTICENTER STUDIES AS TOPIC; PATIENT SELECTION; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIOSURGERY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79956188399     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2010.12.007     Document Type: Short Survey

References (64)

1. Coutard H. Principles of X-ray therapy of malignant diseases. Lancet 1934, 2:l-12.
2. Friberg S., Rudén B.I. Hypofractionation in radiotherapy. An investigation of injured Swedish women, treated for cancer of the breast. Acta Oncol 2009, 48:822-831.
3. Johansson S., Svensson H., Denekamp J. Timescale to the evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. Int J Radiat Oncol Biol Phys 2000, 48:745-750.
4. Veronesi U., Luini A., Del Vecchio M., Greco M., Galimberti V., Merson M., et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 1993, 328:1587-1591.
5. Farrow D.C., Hunt W.C., Samet J.M. Geographic variation in the treatment of localized breast cancer. N Engl J Med 1992, 326:1097-1101.
6. McCarthy E.P., Ngo L.H., Roetzheim R.G., Chirikos T.N., Li D., Drews R.E., et al. Disparities in breast cancer treatment and survival for women with disabilities. Ann Intern Med 2006, 145:637-645.
7. Haybittle J.L., Brinkley D., Houghton J., A'Hern R.P., Baum M. Postoperative radiotherapy and late mortality: evidence from the Cancer Research Campaign trial for early breast cancer. BMJ 1989, 298:1611-1614.
8. Whelan T.J., Pignol J.P., Levine M.N., Julian J.A., MacKenzie R., Parpia S., et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010, 362:513-520.
9. Yarnold J., Ashton A., Bliss J., Homewood J., Harper C., Hanson J., et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 2005, 75:9-17.
10. Bentzen S.M., Agrawal R.K., Aird E.G., Barrett J.M., Barrett-Lee P.J., Bliss J.M., et al. The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008, 9:331-341.
11. Bentzen S.M., Agrawal R.K., Aird E.G., Barrett J.M., Barrett-Lee P.J., Bentzen S.M., et al. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008, 371:1098-1107.
12. Formenti S.C., Gidea-Addeo D., Goldberg J.D., Roses D.F., Guth A., Rosenstein B.S., et al. Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol 2007, 25:2236-2242.
13. Veronesi U., Cascinelli N., Mariani L., Greco M., Saccozzi R., Luini A., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002, 347:1227-1232.
14. King T.A., Bolton J.S., Kuske R.R., Fuhrman G.M., Scroggins T.G., Jiang X.Z. Long-term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for T(is, 1,2) breast cancer. Am J Surg 2000, 180:299-304.
15. Fentiman I.S., Poole C., Tong D., Winter P.J., Gregory W.M., Mayles H.M., et al. Inadequacy of iridium implant as sole radiation treatment for operable breast cancer. Eur J Cancer 1996, 32A:608-611.
16. Vicini F., Beitsch P.D., Quiet C.A., Keleher A.J., Garcia D., Snider H.C., et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer 2008, 112:758-766.
17. Ko E.C., Koprowski C.D., Dickson-Witmer D., Penman E., Sorensen M., Hanlon A.L., et al. Partial versus whole breast irradiation in a community hospital: a retrospective cohort analysis of 200 patients. Brachytherapy 2010, 9:248-253.
18. Dickler A., Dowlatshahi K. Xoft Axxent electronic brachytherapy. Expert Rev Med Devices 2009, 6:27-31.
19. Magee B., Swindell R., Harris M., Banerjee S.S. Prognostic factors for breast recurrence after conservative breast surgery and radiotherapy: results from a randomised trial. Radiother Oncol 1996, 39:223-227.
20. Dodwell D.J., Dyker K., Brown J., Hawkins K., Cohen D., Stead M., et al. A randomised study of whole-breast versus tumour-bed irradiation after local excision and axillary dissection for early breast cancer. Clin Oncol (R Coll Radiol) 2005, 17:618-622.
21. Vicini F., Winter K., Wong J., Pass H., Rabinovitch R., Chafe S., et al. Initial efficacy results of RTOG 0319: three-dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/II breast carcinoma. Int J Radiat Oncol Biol Phys 2010, 77:1120-1127.
22. Veronesi U., Orecchia R., Luini A., Galimberti V., Gatti G., Intra M., et al. Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery: experience with 590 cases. Ann Surg 2005, 242:101-106.
23. Lemanski C., Azria D., Thezenas S., Gutowski M., Saint-Aubert B., Rouanet P., et al. Intraoperative radiotherapy given as a boost for early breast cancer: long-term clinical and cosmetic results. Int J Radiat Oncol Biol Phys 2006, 64:1410-1415.
24. Lemanski C., Azria D., Gourgon-Bourgade S., Gutowski M., Rouanet P., Saint-Aubert B., et al. Intraoperative radiotherapy in early-stage breast cancer: results of the Montpellier phase II trial. Int J Radiat Oncol Biol Phys 2010, 76:698-703.
25. Elliott RL, Deland M, Head JF, Elliott MC. Accelerated partial breast irradiation: Initial experience with the intrabeam system. Surg Oncol 2009; [in press]. doi:10.1016/j.suronc.2009.11.001.
26. Azria D., Bourgier C. Partial breast irradiation: new standard for selected patients. Lancet 2010, 376:71-72.
27. Vaidya J.S., Joseph D.J., Tobias J.S., Bulsara M., Wenz F., Saunders C., et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010, 376:91-102.
28. Beal K., McCormick B., Zelefsky M.J., Borgen P., Fey J., Goldberg J., et al. Single-fraction intraoperative radiotherapy for breast cancer: early cosmetic results. Int J Radiat Oncol Biol Phys 2007, 69:19-24.
29. Clarke M., Collins R., Darby S., Davies C., Elphinstone P., Evans E., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106.
30. Lloyd-Davies R.W., Collins C.D., Swan A.V. Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984). Urology 1990, 36:107-111.
31. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999, 43:1095-1101.
32. Fowler J., Chappell R., Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 2001, 50:1021-1031.
33. Duchesne G.M., Peters L.J. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 44:747-748.
34. Brenner D.J., Martinez A.A., Edmundson G.K., Mitchell C., Thames H.D., Armour E.P. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52:6-13.
35. Chappell R., Fowler J., Ritter M. New data on the value of alpha/beta-evidence mounts that it is low. Int J Radiat Oncol Biol Phys 2004, 60:1002-1006.
36. Lukka H., Haytet C., Warde P., Morris J., Julian J., Gospodarowicz M., et al. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Radiother Oncol 2003, 69:S7.
37. Lukka H., Hayter C., Julian J.A., Warde P., Morris W.J., Gospodarowicz M., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23:6132-6138.
38. Miles E.F., Lee W.R. Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol 2008, 18:41-47.
39. Arcangeli G., Saracino B., Gomellini S., Petrongari M.G., Arcangeli S., Sentinelli S., et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78:11-18.
40. Pollack A., Hanlon A.L., Horwitz E.M., Feigenberg S.J., Konski A.A., Movsas B., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006, 64:518-526.
41. Martinez A.A., Demanes D.J., Ghilezan M., Schour L., Mitchell C., Gustafson G.S. Five-year results using HDR monotherapy for patients with favorable prostate cancer. Brachytherapy 2008, 7:92.
42. Martinez A.A., Demanes J., Vargas C., Schour L., Ghilezan M., Gustafson G.S. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010, 33:481-488.
43. Madsen B.L., Hsi R.A., Pham H.T., Fowler J.F., Esagui L., Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67:1099-1105.
44. King C.R., Brooks J.D., Gill H., Pawlicki T., Cotrutz C., Presti J.C. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009, 73:1043-1048.
45. Scott W.J., Howington J., Feigenberg S., Movsas B., Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:234S-242S.
46. McGarry R.C., Papiez L., Williams M., Whitford T., Timmerman R.D. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 2005, 63:1010-1015.
47. Nagata Y., Takayama K., Matsuo Y., Norihisa Y., Mizowaki T., Sakamoto T., et al. Clinical outcomes of a phase I/II study of 48Gy of stereotactic body radiotherapy in four fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63:1427-1431.
48. Timmerman R., Paulus R., Galvin J., Michalski J., Straube W., Bradley J., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076.
49. Timmerman R., McGarry R., Yiannoutsos C., Papiez L., Tudor K., DeLuca J., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839.
50. Jin J.Y., Kong F.M., Chetty I.J., Ajlouni M., Ryu S., Ten Haken R., et al. Impact of fraction size on lung radiation toxicity: hypofractionation may be beneficial in dose escalation of radiotherapy for lung cancers. Int J Radiat Oncol Biol Phys 2010, 76:782-788.
51. Szeifert G.T., Atteberry D.S., Kondziolka D., Levivier M., Lunsford L.D. Cerebral metastases pathology after radiosurgery: a multicenter study. Cancer 2006, 106:2672-2681.
52. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
53. Lee Y., Auh S.L., Wang Y., Burnette B., Wang Y., Meng Y., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
54. Kao J., Packer S., Vu H.L., Schwartz M.E., Sung M.W., Stock R.G., et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009, 115:3571-3580.
55. Brenner D.J. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol 2008, 18:234-239.
56. Kirkpatrick J.P., Meyer J.J., Marks L.B. The linear-quadratic model is inappropriate to model high dose per fraction effects of radiosurgery. Semin Radiat Oncol 2008, 18:240-243.
57. Kocher M., Treuer H., Voges J., Hoevels M., Sturm V., Müller R.P. Computer simulation of cytotoxic and vascular effects of radiosurgery in solid and necrotic brain metastases. Radiother Oncol 2000, 54:149-156.
58. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
59. Bentzen S. Preventing or reducing late side effects of radiation therapy: radiobiology meets pathology. Nat Rev Cancer 2006, 6:702-713.
60. Barnett G.C., West C.M., Dunning A.M., Elliott R.M., Coles C.E., Pharoah P.D., et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009, 9:134-142.
61. Azria D., Ozsahin M., Kramar A., Peters S., Atencio D.P., Crompton N.E., et al. Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 2008, 14:6284-6288.
62. Azria D, Betz M, Bourgier C, Sozzi WJ, Ozsahin M. Identifying patients at risk for late radiation-induced toxicity. Crit Rev Oncol Hematol 2010; [in press]. doi:10.1016/j.critrevonc.2010.08.003.
63. Ozsahin M., Crompton N.E., Gourgou S., Kramar A., Li L., Shi Y., et al. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res 2005, 11:7426-7433.
64. Azria D., Belkacemi Y., Romieu G., Gourgou S., Gutowski M., Zaman K., et al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol 2010, 11:258-265.